CAS 792173-99-0: 1-(2-Methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea
Formula:C17H13N5O2
InChI:InChI=1/C17H13N5O2/c1-10-20-12-5-4-11(9-15(12)24-10)21-17(23)22-14-6-8-18-13-3-2-7-19-16(13)14/h2-9H,1H3,(H2,18,21,22,23)
- Synonyms:
- Sb334867
- Sb 334867
- Urea, N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl-

N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl-Urea
CAS:792173-99-0
Formula:
C17H13N5O2
Purity:
99%
Color and Shape:
Solid
Molecular weight:
319.3174
Ref: IN-DA0035AB
1mg | 33.00 € | ||
5mg | 59.00 € |
Estimated delivery in United States, on Friday 11 Apr 2025

1-(2-Methylbenzo[D]Oxazol-6-Yl)-3-(1,5-Naphthyridin-4-Yl)Urea
CAS:792173-99-0
Molecular weight:
319.32g/mol
Ref: 54-OR1023982
1g | 1,790.00 € | ||
100mg | 334.00 € | ||
250mg | 549.00 € |
Estimated delivery in United States, on Monday 14 Apr 2025

SB-334867 free base
CAS:792173-99-0
SB-334867 free base (SB334867A free base) is a selective orexin-1 (OX1) receptor antagonist.
Formula:
C17H13N5O2
Purity:
100% - 99.91%
Color and Shape:
Solid
Molecular weight:
319.32
Ref: TM-T6140
2mg | 42.00 € | ||
5mg | 70.00 € | ||
10mg | 99.00 € | ||
25mg | 160.00 € | ||
50mg | 226.00 € | ||
100mg | 338.00 € | ||
200mg | 502.00 € | ||
1mL*10mM (DMSO) | 78.00 € |
Estimated delivery in United States, on Monday 21 Apr 2025

SB 334867
Controlled ProductCAS:792173-99-0
Formula:
C17H13N5O2
Color and Shape:
Neat
Molecular weight:
319.32
Ref: TR-S155085
10mg | 266.00 € | ||
100mg | 1,786.00 € |
Estimated delivery in United States, on Thursday 22 May 2025

SB 334867
CAS:792173-99-0
A non-peptide antagonist of orexin receptors, selective for subtype OX1 over OX2 (50-fold more). Systemic …
Formula:
C17H13N5O2
Purity:
Min. 95%
Molecular weight:
319.32 g/mol
Ref: 3D-BS162612
2mg | 331.00 € | ||
5mg | 410.00 € | ||
10mg | 584.00 € | ||
25mg | 830.00 € |
Estimated delivery in United States, on Friday 23 May 2025

1-(2-Methylbenzo[d]oxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea
CAS:792173-99-0
Purity:
95.0%
Molecular weight:
319.3240051269531
Ref: 10-F431122
250mg | Discontinued | Request information |